nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—CYP2E1—Ritonavir—acquired immunodeficiency syndrome	0.0227	0.0392	CbGbCtD
Carvedilol—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0204	0.0352	CbGbCtD
Carvedilol—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0192	0.0331	CbGbCtD
Carvedilol—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0192	0.0331	CbGbCtD
Carvedilol—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0184	0.0317	CbGbCtD
Carvedilol—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0173	0.0299	CbGbCtD
Carvedilol—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0173	0.0298	CbGbCtD
Carvedilol—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0173	0.0298	CbGbCtD
Carvedilol—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0168	0.029	CbGbCtD
Carvedilol—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0168	0.0289	CbGbCtD
Carvedilol—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0158	0.0272	CbGbCtD
Carvedilol—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0158	0.0272	CbGbCtD
Carvedilol—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0156	0.0269	CbGbCtD
Carvedilol—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0156	0.0269	CbGbCtD
Carvedilol—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0152	0.0261	CbGbCtD
Carvedilol—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0145	0.0251	CbGbCtD
Carvedilol—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0143	0.0246	CbGbCtD
Carvedilol—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0143	0.0246	CbGbCtD
Carvedilol—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0135	0.0233	CbGbCtD
Carvedilol—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0131	0.0227	CbGbCtD
Carvedilol—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0131	0.0226	CbGbCtD
Carvedilol—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0131	0.0226	CbGbCtD
Carvedilol—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0127	0.0219	CbGbCtD
Carvedilol—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0123	0.0213	CbGbCtD
Carvedilol—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.012	0.0206	CbGbCtD
Carvedilol—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0118	0.0204	CbGbCtD
Carvedilol—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0118	0.0204	CbGbCtD
Carvedilol—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0115	0.0198	CbGbCtD
Carvedilol—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0115	0.0198	CbGbCtD
Carvedilol—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0114	0.0196	CbGbCtD
Carvedilol—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.011	0.019	CbGbCtD
Carvedilol—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0108	0.0187	CbGbCtD
Carvedilol—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0108	0.0187	CbGbCtD
Carvedilol—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0107	0.0184	CbGbCtD
Carvedilol—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.01	0.0173	CbGbCtD
Carvedilol—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.01	0.0173	CbGbCtD
Carvedilol—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00909	0.0157	CbGbCtD
Carvedilol—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00909	0.0157	CbGbCtD
Carvedilol—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00852	0.0147	CbGbCtD
Carvedilol—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00784	0.0135	CbGbCtD
Carvedilol—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00761	0.0131	CbGbCtD
Carvedilol—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00689	0.0119	CbGbCtD
Carvedilol—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00689	0.0119	CbGbCtD
Carvedilol—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0066	0.0114	CbGbCtD
Carvedilol—NPPB—blood plasma—acquired immunodeficiency syndrome	0.00421	0.0384	CbGeAlD
Carvedilol—HIF1A—nerve—acquired immunodeficiency syndrome	0.00333	0.0304	CbGeAlD
Carvedilol—SELE—endothelium—acquired immunodeficiency syndrome	0.0032	0.0292	CbGeAlD
Carvedilol—VCAM1—endothelium—acquired immunodeficiency syndrome	0.00294	0.0269	CbGeAlD
Carvedilol—SELE—blood plasma—acquired immunodeficiency syndrome	0.00284	0.026	CbGeAlD
Carvedilol—HIF1A—endothelium—acquired immunodeficiency syndrome	0.00283	0.0259	CbGeAlD
Carvedilol—GJA1—endothelium—acquired immunodeficiency syndrome	0.00275	0.0251	CbGeAlD
Carvedilol—VCAM1—blood plasma—acquired immunodeficiency syndrome	0.00261	0.0239	CbGeAlD
Carvedilol—GJA1—Lopinavir—Ritonavir—acquired immunodeficiency syndrome	0.00214	0.377	CbGdCrCtD
Carvedilol—GJA1—Lopinavir—Indinavir—acquired immunodeficiency syndrome	0.00191	0.336	CbGdCrCtD
Carvedilol—NPPB—lymphoid tissue—acquired immunodeficiency syndrome	0.00164	0.015	CbGeAlD
Carvedilol—GJA1—Lopinavir—Saquinavir—acquired immunodeficiency syndrome	0.00162	0.286	CbGdCrCtD
Carvedilol—NPPB—blood—acquired immunodeficiency syndrome	0.00154	0.0141	CbGeAlD
Carvedilol—VCAM1—retina—acquired immunodeficiency syndrome	0.00143	0.0131	CbGeAlD
Carvedilol—HIF1A—retina—acquired immunodeficiency syndrome	0.00138	0.0126	CbGeAlD
Carvedilol—SELE—skin of body—acquired immunodeficiency syndrome	0.00137	0.0125	CbGeAlD
Carvedilol—GJA1—retina—acquired immunodeficiency syndrome	0.00134	0.0122	CbGeAlD
Carvedilol—NPPB—nervous system—acquired immunodeficiency syndrome	0.00125	0.0114	CbGeAlD
Carvedilol—HIF1A—skin of body—acquired immunodeficiency syndrome	0.00121	0.011	CbGeAlD
Carvedilol—NPPB—central nervous system—acquired immunodeficiency syndrome	0.0012	0.011	CbGeAlD
Carvedilol—GJA1—skin of body—acquired immunodeficiency syndrome	0.00117	0.0107	CbGeAlD
Carvedilol—NDUFC2—retina—acquired immunodeficiency syndrome	0.00116	0.0106	CbGeAlD
Carvedilol—SELE—lymphoid tissue—acquired immunodeficiency syndrome	0.00111	0.0101	CbGeAlD
Carvedilol—SELE—digestive system—acquired immunodeficiency syndrome	0.00109	0.00999	CbGeAlD
Carvedilol—SELE—blood—acquired immunodeficiency syndrome	0.00104	0.00951	CbGeAlD
Carvedilol—VCAM1—lymphoid tissue—acquired immunodeficiency syndrome	0.00102	0.0093	CbGeAlD
Carvedilol—VCAM1—digestive system—acquired immunodeficiency syndrome	0.00101	0.00919	CbGeAlD
Carvedilol—SELE—spinal cord—acquired immunodeficiency syndrome	0.001	0.00917	CbGeAlD
Carvedilol—HIF1A—lymphoid tissue—acquired immunodeficiency syndrome	0.000979	0.00895	CbGeAlD
Carvedilol—HIF1A—digestive system—acquired immunodeficiency syndrome	0.000967	0.00884	CbGeAlD
Carvedilol—SELE—vagina—acquired immunodeficiency syndrome	0.000965	0.00882	CbGeAlD
Carvedilol—VCAM1—blood—acquired immunodeficiency syndrome	0.000958	0.00875	CbGeAlD
Carvedilol—NPPB—brain—acquired immunodeficiency syndrome	0.000956	0.00874	CbGeAlD
Carvedilol—GJA1—lymphoid tissue—acquired immunodeficiency syndrome	0.00095	0.00868	CbGeAlD
Carvedilol—GJA1—digestive system—acquired immunodeficiency syndrome	0.000938	0.00857	CbGeAlD
Carvedilol—VCAM1—bone marrow—acquired immunodeficiency syndrome	0.000927	0.00847	CbGeAlD
Carvedilol—VCAM1—spinal cord—acquired immunodeficiency syndrome	0.000923	0.00843	CbGeAlD
Carvedilol—HIF1A—blood—acquired immunodeficiency syndrome	0.000921	0.00842	CbGeAlD
Carvedilol—SELE—lung—acquired immunodeficiency syndrome	0.000913	0.00834	CbGeAlD
Carvedilol—HIF1A—bone marrow—acquired immunodeficiency syndrome	0.000891	0.00815	CbGeAlD
Carvedilol—VCAM1—vagina—acquired immunodeficiency syndrome	0.000888	0.00811	CbGeAlD
Carvedilol—HIF1A—spinal cord—acquired immunodeficiency syndrome	0.000888	0.00811	CbGeAlD
Carvedilol—GJA1—bone marrow—acquired immunodeficiency syndrome	0.000865	0.0079	CbGeAlD
Carvedilol—GJA1—spinal cord—acquired immunodeficiency syndrome	0.000861	0.00787	CbGeAlD
Carvedilol—HIF1A—vagina—acquired immunodeficiency syndrome	0.000854	0.00781	CbGeAlD
Carvedilol—SELE—nervous system—acquired immunodeficiency syndrome	0.000845	0.00772	CbGeAlD
Carvedilol—VCAM1—lung—acquired immunodeficiency syndrome	0.00084	0.00767	CbGeAlD
Carvedilol—GJA1—vagina—acquired immunodeficiency syndrome	0.000828	0.00757	CbGeAlD
Carvedilol—NDUFC2—lymphoid tissue—acquired immunodeficiency syndrome	0.000827	0.00756	CbGeAlD
Carvedilol—NDUFC2—digestive system—acquired immunodeficiency syndrome	0.000817	0.00746	CbGeAlD
Carvedilol—SELE—central nervous system—acquired immunodeficiency syndrome	0.000814	0.00744	CbGeAlD
Carvedilol—HIF1A—lung—acquired immunodeficiency syndrome	0.000808	0.00738	CbGeAlD
Carvedilol—GJA1—lung—acquired immunodeficiency syndrome	0.000783	0.00716	CbGeAlD
Carvedilol—NDUFC2—blood—acquired immunodeficiency syndrome	0.000778	0.00711	CbGeAlD
Carvedilol—VCAM1—nervous system—acquired immunodeficiency syndrome	0.000777	0.00711	CbGeAlD
Carvedilol—NDUFC2—bone marrow—acquired immunodeficiency syndrome	0.000753	0.00688	CbGeAlD
Carvedilol—NDUFC2—spinal cord—acquired immunodeficiency syndrome	0.00075	0.00685	CbGeAlD
Carvedilol—VCAM1—central nervous system—acquired immunodeficiency syndrome	0.000748	0.00684	CbGeAlD
Carvedilol—HIF1A—nervous system—acquired immunodeficiency syndrome	0.000748	0.00684	CbGeAlD
Carvedilol—GJA1—nervous system—acquired immunodeficiency syndrome	0.000726	0.00663	CbGeAlD
Carvedilol—NDUFC2—vagina—acquired immunodeficiency syndrome	0.000721	0.00659	CbGeAlD
Carvedilol—HIF1A—central nervous system—acquired immunodeficiency syndrome	0.00072	0.00658	CbGeAlD
Carvedilol—GJA1—central nervous system—acquired immunodeficiency syndrome	0.000699	0.00638	CbGeAlD
Carvedilol—VEGFA—bone marrow—acquired immunodeficiency syndrome	0.000683	0.00624	CbGeAlD
Carvedilol—NDUFC2—lung—acquired immunodeficiency syndrome	0.000682	0.00623	CbGeAlD
Carvedilol—VEGFA—spinal cord—acquired immunodeficiency syndrome	0.00068	0.00621	CbGeAlD
Carvedilol—XDH—digestive system—acquired immunodeficiency syndrome	0.000659	0.00603	CbGeAlD
Carvedilol—VEGFA—vagina—acquired immunodeficiency syndrome	0.000654	0.00598	CbGeAlD
Carvedilol—SELE—brain—acquired immunodeficiency syndrome	0.000646	0.0059	CbGeAlD
Carvedilol—NDUFC2—nervous system—acquired immunodeficiency syndrome	0.000632	0.00577	CbGeAlD
Carvedilol—SELE—lymph node—acquired immunodeficiency syndrome	0.000624	0.0057	CbGeAlD
Carvedilol—VEGFA—lung—acquired immunodeficiency syndrome	0.000619	0.00565	CbGeAlD
Carvedilol—NDUFC2—central nervous system—acquired immunodeficiency syndrome	0.000608	0.00556	CbGeAlD
Carvedilol—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000598	0.00546	CbGeAlD
Carvedilol—VCAM1—brain—acquired immunodeficiency syndrome	0.000594	0.00543	CbGeAlD
Carvedilol—PTGS1—endothelium—acquired immunodeficiency syndrome	0.000583	0.00533	CbGeAlD
Carvedilol—XDH—vagina—acquired immunodeficiency syndrome	0.000582	0.00532	CbGeAlD
Carvedilol—VCAM1—lymph node—acquired immunodeficiency syndrome	0.000574	0.00525	CbGeAlD
Carvedilol—HIF1A—brain—acquired immunodeficiency syndrome	0.000572	0.00522	CbGeAlD
Carvedilol—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000567	0.00519	CbGeAlD
Carvedilol—GJA1—brain—acquired immunodeficiency syndrome	0.000555	0.00507	CbGeAlD
Carvedilol—HIF1A—lymph node—acquired immunodeficiency syndrome	0.000552	0.00505	CbGeAlD
Carvedilol—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.00055	0.00502	CbGeAlD
Carvedilol—CYP2E1—blood plasma—acquired immunodeficiency syndrome	0.000538	0.00491	CbGeAlD
Carvedilol—GJA1—lymph node—acquired immunodeficiency syndrome	0.000536	0.0049	CbGeAlD
Carvedilol—PTGS1—blood plasma—acquired immunodeficiency syndrome	0.000518	0.00473	CbGeAlD
Carvedilol—NDUFC2—brain—acquired immunodeficiency syndrome	0.000483	0.00441	CbGeAlD
Carvedilol—NDUFC2—lymph node—acquired immunodeficiency syndrome	0.000466	0.00426	CbGeAlD
Carvedilol—VEGFA—brain—acquired immunodeficiency syndrome	0.000438	0.004	CbGeAlD
Carvedilol—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000433	0.00395	CbGeAlD
Carvedilol—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000426	0.00389	CbGeAlD
Carvedilol—VEGFA—lymph node—acquired immunodeficiency syndrome	0.000423	0.00387	CbGeAlD
Carvedilol—ADRA1B—nervous system—acquired immunodeficiency syndrome	0.000383	0.0035	CbGeAlD
Carvedilol—ADRA1D—nervous system—acquired immunodeficiency syndrome	0.000374	0.00342	CbGeAlD
Carvedilol—ADRA1B—central nervous system—acquired immunodeficiency syndrome	0.000368	0.00337	CbGeAlD
Carvedilol—ADRA1D—central nervous system—acquired immunodeficiency syndrome	0.00036	0.00329	CbGeAlD
Carvedilol—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000306	0.0028	CbGeAlD
Carvedilol—ADRB1—lung—acquired immunodeficiency syndrome	0.000294	0.00268	CbGeAlD
Carvedilol—ADRA1B—brain—acquired immunodeficiency syndrome	0.000292	0.00267	CbGeAlD
Carvedilol—ADRA1D—brain—acquired immunodeficiency syndrome	0.000286	0.00261	CbGeAlD
Carvedilol—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000283	0.00259	CbGeAlD
Carvedilol—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.000281	0.00257	CbGeAlD
Carvedilol—ADRB1—nervous system—acquired immunodeficiency syndrome	0.000272	0.00248	CbGeAlD
Carvedilol—ADRA1A—blood—acquired immunodeficiency syndrome	0.000265	0.00242	CbGeAlD
Carvedilol—ADRB1—central nervous system—acquired immunodeficiency syndrome	0.000262	0.00239	CbGeAlD
Carvedilol—KCNH2—blood—acquired immunodeficiency syndrome	0.000256	0.00234	CbGeAlD
Carvedilol—ADRA2C—blood—acquired immunodeficiency syndrome	0.000252	0.00231	CbGeAlD
Carvedilol—PTGS1—skin of body—acquired immunodeficiency syndrome	0.000249	0.00228	CbGeAlD
Carvedilol—KCNH2—bone marrow—acquired immunodeficiency syndrome	0.000247	0.00226	CbGeAlD
Carvedilol—KCNH2—spinal cord—acquired immunodeficiency syndrome	0.000246	0.00225	CbGeAlD
Carvedilol—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.000243	0.00222	CbGeAlD
Carvedilol—KCNH2—vagina—acquired immunodeficiency syndrome	0.000237	0.00217	CbGeAlD
Carvedilol—ADRA2C—vagina—acquired immunodeficiency syndrome	0.000234	0.00214	CbGeAlD
Carvedilol—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.00023	0.0021	CbGeAlD
Carvedilol—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000227	0.00207	CbGeAlD
Carvedilol—ADRA2C—lung—acquired immunodeficiency syndrome	0.000221	0.00202	CbGeAlD
Carvedilol—CYP1A2—blood—acquired immunodeficiency syndrome	0.000219	0.002	CbGeAlD
Carvedilol—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000218	0.00199	CbGeAlD
Carvedilol—CYP1A1—blood—acquired immunodeficiency syndrome	0.000216	0.00197	CbGeAlD
Carvedilol—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.000215	0.00196	CbGeAlD
Carvedilol—CYP2E1—lymphoid tissue—acquired immunodeficiency syndrome	0.000209	0.00191	CbGeAlD
Carvedilol—CYP2C9—blood—acquired immunodeficiency syndrome	0.000208	0.0019	CbGeAlD
Carvedilol—ADRB1—brain—acquired immunodeficiency syndrome	0.000208	0.0019	CbGeAlD
Carvedilol—KCNH2—nervous system—acquired immunodeficiency syndrome	0.000208	0.0019	CbGeAlD
Carvedilol—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.000207	0.00189	CbGeAlD
Carvedilol—CYP2E1—digestive system—acquired immunodeficiency syndrome	0.000207	0.00189	CbGeAlD
Carvedilol—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.000205	0.00187	CbGeAlD
Carvedilol—ADRA2A—blood—acquired immunodeficiency syndrome	0.000201	0.00184	CbGeAlD
Carvedilol—CYP1A1—vagina—acquired immunodeficiency syndrome	0.0002	0.00183	CbGeAlD
Carvedilol—KCNH2—central nervous system—acquired immunodeficiency syndrome	0.0002	0.00183	CbGeAlD
Carvedilol—PTGS1—digestive system—acquired immunodeficiency syndrome	0.000199	0.00182	CbGeAlD
Carvedilol—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.000197	0.0018	CbGeAlD
Carvedilol—CYP2E1—blood—acquired immunodeficiency syndrome	0.000197	0.0018	CbGeAlD
Carvedilol—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.000194	0.00177	CbGeAlD
Carvedilol—CYP1A2—lung—acquired immunodeficiency syndrome	0.000192	0.00175	CbGeAlD
Carvedilol—CYP2E1—spinal cord—acquired immunodeficiency syndrome	0.00019	0.00173	CbGeAlD
Carvedilol—PTGS1—blood—acquired immunodeficiency syndrome	0.00019	0.00173	CbGeAlD
Carvedilol—CYP1A1—lung—acquired immunodeficiency syndrome	0.000189	0.00173	CbGeAlD
Carvedilol—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000187	0.00171	CbGeAlD
Carvedilol—PTGS1—spinal cord—acquired immunodeficiency syndrome	0.000183	0.00167	CbGeAlD
Carvedilol—ADRA2A—lung—acquired immunodeficiency syndrome	0.000177	0.00161	CbGeAlD
Carvedilol—PTGS1—vagina—acquired immunodeficiency syndrome	0.000176	0.00161	CbGeAlD
Carvedilol—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.000175	0.0016	CbGeAlD
Carvedilol—CYP2E1—lung—acquired immunodeficiency syndrome	0.000173	0.00158	CbGeAlD
Carvedilol—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.000169	0.00154	CbGeAlD
Carvedilol—ABCB1—retina—acquired immunodeficiency syndrome	0.000168	0.00153	CbGeAlD
Carvedilol—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000166	0.00152	CbGeAlD
Carvedilol—PTGS1—lung—acquired immunodeficiency syndrome	0.000166	0.00152	CbGeAlD
Carvedilol—ADRA1A—brain—acquired immunodeficiency syndrome	0.000164	0.0015	CbGeAlD
Carvedilol—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000164	0.0015	CbGeAlD
Carvedilol—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000163	0.00149	CbGeAlD
Carvedilol—CYP2E1—nervous system—acquired immunodeficiency syndrome	0.00016	0.00146	CbGeAlD
Carvedilol—KCNH2—brain—acquired immunodeficiency syndrome	0.000159	0.00145	CbGeAlD
Carvedilol—CYP3A4—blood—acquired immunodeficiency syndrome	0.000158	0.00145	CbGeAlD
Carvedilol—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000157	0.00144	CbGeAlD
Carvedilol—ADRA2C—brain—acquired immunodeficiency syndrome	0.000157	0.00143	CbGeAlD
Carvedilol—CYP2D6—blood—acquired immunodeficiency syndrome	0.000156	0.00143	CbGeAlD
Carvedilol—PTGS1—nervous system—acquired immunodeficiency syndrome	0.000154	0.00141	CbGeAlD
Carvedilol—CYP2E1—central nervous system—acquired immunodeficiency syndrome	0.000154	0.00141	CbGeAlD
Carvedilol—KCNH2—lymph node—acquired immunodeficiency syndrome	0.000153	0.0014	CbGeAlD
Carvedilol—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.000151	0.00138	CbGeAlD
Carvedilol—PTGS1—central nervous system—acquired immunodeficiency syndrome	0.000148	0.00136	CbGeAlD
Carvedilol—CYP1A1—brain—acquired immunodeficiency syndrome	0.000134	0.00122	CbGeAlD
Carvedilol—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.00013	0.00118	CbGeAlD
Carvedilol—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000129	0.00118	CbGeAlD
Carvedilol—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000127	0.00116	CbGeAlD
Carvedilol—ADRA2A—brain—acquired immunodeficiency syndrome	0.000125	0.00114	CbGeAlD
Carvedilol—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000124	0.00113	CbGeAlD
Carvedilol—CYP2E1—brain—acquired immunodeficiency syndrome	0.000122	0.00112	CbGeAlD
Carvedilol—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000122	0.00111	CbGeAlD
Carvedilol—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.000121	0.0011	CbGeAlD
Carvedilol—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000119	0.00109	CbGeAlD
Carvedilol—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000118	0.00108	CbGeAlD
Carvedilol—PTGS1—brain—acquired immunodeficiency syndrome	0.000118	0.00108	CbGeAlD
Carvedilol—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000115	0.000489	CcSEcCtD
Carvedilol—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000115	0.000489	CcSEcCtD
Carvedilol—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000114	0.000488	CcSEcCtD
Carvedilol—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000114	0.000488	CcSEcCtD
Carvedilol—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000114	0.000486	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000114	0.000486	CcSEcCtD
Carvedilol—PTGS1—lymph node—acquired immunodeficiency syndrome	0.000114	0.00104	CbGeAlD
Carvedilol—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000114	0.000485	CcSEcCtD
Carvedilol—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000114	0.000484	CcSEcCtD
Carvedilol—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000114	0.000484	CcSEcCtD
Carvedilol—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000113	0.000484	CcSEcCtD
Carvedilol—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000113	0.000484	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000113	0.000483	CcSEcCtD
Carvedilol—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000113	0.000483	CcSEcCtD
Carvedilol—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000113	0.000482	CcSEcCtD
Carvedilol—Pain—Indinavir—acquired immunodeficiency syndrome	0.000113	0.00048	CcSEcCtD
Carvedilol—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000113	0.00048	CcSEcCtD
Carvedilol—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000113	0.00048	CcSEcCtD
Carvedilol—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000112	0.000479	CcSEcCtD
Carvedilol—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000112	0.000479	CcSEcCtD
Carvedilol—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000479	CcSEcCtD
Carvedilol—ABCB1—blood—acquired immunodeficiency syndrome	0.000112	0.00103	CbGeAlD
Carvedilol—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000112	0.000478	CcSEcCtD
Carvedilol—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000112	0.000477	CcSEcCtD
Carvedilol—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000112	0.000477	CcSEcCtD
Carvedilol—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000112	0.000476	CcSEcCtD
Carvedilol—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000112	0.000476	CcSEcCtD
Carvedilol—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000112	0.000476	CcSEcCtD
Carvedilol—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000111	0.000475	CcSEcCtD
Carvedilol—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000111	0.000475	CcSEcCtD
Carvedilol—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000111	0.000474	CcSEcCtD
Carvedilol—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000111	0.000474	CcSEcCtD
Carvedilol—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000111	0.000473	CcSEcCtD
Carvedilol—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000111	0.000473	CcSEcCtD
Carvedilol—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000111	0.000473	CcSEcCtD
Carvedilol—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000111	0.000472	CcSEcCtD
Carvedilol—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000111	0.000471	CcSEcCtD
Carvedilol—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000111	0.000471	CcSEcCtD
Carvedilol—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000111	0.000471	CcSEcCtD
Carvedilol—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000111	0.000471	CcSEcCtD
Carvedilol—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.000469	CcSEcCtD
Carvedilol—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00011	0.000468	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.00011	0.000468	CcSEcCtD
Carvedilol—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.00011	0.000467	CcSEcCtD
Carvedilol—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.000465	CcSEcCtD
Carvedilol—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.000464	CcSEcCtD
Carvedilol—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000109	0.000992	CbGeAlD
Carvedilol—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000109	0.000462	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000108	0.000462	CcSEcCtD
Carvedilol—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000108	0.000462	CcSEcCtD
Carvedilol—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.000461	CcSEcCtD
Carvedilol—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000108	0.000988	CbGeAlD
Carvedilol—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000461	CcSEcCtD
Carvedilol—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.000461	CcSEcCtD
Carvedilol—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000108	0.000461	CcSEcCtD
Carvedilol—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000108	0.000459	CcSEcCtD
Carvedilol—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000108	0.000459	CcSEcCtD
Carvedilol—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000108	0.000459	CcSEcCtD
Carvedilol—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000108	0.000459	CcSEcCtD
Carvedilol—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000107	0.000458	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.000458	CcSEcCtD
Carvedilol—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.000457	CcSEcCtD
Carvedilol—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000107	0.000457	CcSEcCtD
Carvedilol—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.000457	CcSEcCtD
Carvedilol—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000107	0.000456	CcSEcCtD
Carvedilol—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000107	0.000456	CcSEcCtD
Carvedilol—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000455	CcSEcCtD
Carvedilol—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000454	CcSEcCtD
Carvedilol—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000106	0.000453	CcSEcCtD
Carvedilol—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000106	0.000453	CcSEcCtD
Carvedilol—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000106	0.000453	CcSEcCtD
Carvedilol—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000106	0.000453	CcSEcCtD
Carvedilol—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000106	0.000452	CcSEcCtD
Carvedilol—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000106	0.000452	CcSEcCtD
Carvedilol—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000452	CcSEcCtD
Carvedilol—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000106	0.000451	CcSEcCtD
Carvedilol—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000106	0.00045	CcSEcCtD
Carvedilol—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000105	0.000449	CcSEcCtD
Carvedilol—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000105	0.000449	CcSEcCtD
Carvedilol—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000105	0.000449	CcSEcCtD
Carvedilol—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000449	CcSEcCtD
Carvedilol—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.000447	CcSEcCtD
Carvedilol—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000105	0.000447	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000105	0.000446	CcSEcCtD
Carvedilol—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000105	0.000446	CcSEcCtD
Carvedilol—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000104	0.000444	CcSEcCtD
Carvedilol—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000444	CcSEcCtD
Carvedilol—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000104	0.000444	CcSEcCtD
Carvedilol—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000104	0.000444	CcSEcCtD
Carvedilol—ABCB1—vagina—acquired immunodeficiency syndrome	0.000104	0.00095	CbGeAlD
Carvedilol—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000104	0.000443	CcSEcCtD
Carvedilol—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000104	0.000442	CcSEcCtD
Carvedilol—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000104	0.000441	CcSEcCtD
Carvedilol—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000441	CcSEcCtD
Carvedilol—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000439	CcSEcCtD
Carvedilol—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000103	0.000439	CcSEcCtD
Carvedilol—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000103	0.000439	CcSEcCtD
Carvedilol—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000439	CcSEcCtD
Carvedilol—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000103	0.000438	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000438	CcSEcCtD
Carvedilol—Rash—Stavudine—acquired immunodeficiency syndrome	0.000103	0.000438	CcSEcCtD
Carvedilol—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000437	CcSEcCtD
Carvedilol—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000103	0.000437	CcSEcCtD
Carvedilol—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.000437	CcSEcCtD
Carvedilol—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000437	CcSEcCtD
Carvedilol—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000102	0.000436	CcSEcCtD
Carvedilol—Headache—Stavudine—acquired immunodeficiency syndrome	0.000102	0.000435	CcSEcCtD
Carvedilol—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000102	0.000435	CcSEcCtD
Carvedilol—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000434	CcSEcCtD
Carvedilol—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000434	CcSEcCtD
Carvedilol—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000434	CcSEcCtD
Carvedilol—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000102	0.000434	CcSEcCtD
Carvedilol—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000102	0.000433	CcSEcCtD
Carvedilol—Rash—Abacavir—acquired immunodeficiency syndrome	0.000101	0.000431	CcSEcCtD
Carvedilol—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000101	0.000431	CcSEcCtD
Carvedilol—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000431	CcSEcCtD
Carvedilol—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000431	CcSEcCtD
Carvedilol—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.00043	CcSEcCtD
Carvedilol—Headache—Abacavir—acquired immunodeficiency syndrome	0.000101	0.000428	CcSEcCtD
Carvedilol—Infection—Lamivudine—acquired immunodeficiency syndrome	0.0001	0.000428	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.0001	0.000427	CcSEcCtD
Carvedilol—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.0001	0.000427	CcSEcCtD
Carvedilol—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.0001	0.000427	CcSEcCtD
Carvedilol—Insomnia—Ritonavir—acquired immunodeficiency syndrome	9.96e-05	0.000424	CcSEcCtD
Carvedilol—Shock—Lamivudine—acquired immunodeficiency syndrome	9.94e-05	0.000424	CcSEcCtD
Carvedilol—Hypotension—Saquinavir—acquired immunodeficiency syndrome	9.9e-05	0.000422	CcSEcCtD
Carvedilol—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	9.9e-05	0.000422	CcSEcCtD
Carvedilol—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	9.88e-05	0.000421	CcSEcCtD
Carvedilol—Urticaria—Efavirenz—acquired immunodeficiency syndrome	9.88e-05	0.000421	CcSEcCtD
Carvedilol—ABCB1—lung—acquired immunodeficiency syndrome	9.84e-05	0.000899	CbGeAlD
Carvedilol—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	9.83e-05	0.000419	CcSEcCtD
Carvedilol—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	9.83e-05	0.000419	CcSEcCtD
Carvedilol—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	9.82e-05	0.000418	CcSEcCtD
Carvedilol—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	9.81e-05	0.000418	CcSEcCtD
Carvedilol—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	9.81e-05	0.000418	CcSEcCtD
Carvedilol—Somnolence—Ritonavir—acquired immunodeficiency syndrome	9.79e-05	0.000417	CcSEcCtD
Carvedilol—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	9.77e-05	0.000416	CcSEcCtD
Carvedilol—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	9.73e-05	0.000415	CcSEcCtD
Carvedilol—Nausea—Nelfinavir—acquired immunodeficiency syndrome	9.71e-05	0.000414	CcSEcCtD
Carvedilol—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	9.7e-05	0.000413	CcSEcCtD
Carvedilol—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	9.69e-05	0.000413	CcSEcCtD
Carvedilol—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	9.69e-05	0.000413	CcSEcCtD
Carvedilol—CYP2D6—brain—acquired immunodeficiency syndrome	9.68e-05	0.000884	CbGeAlD
Carvedilol—Nausea—Stavudine—acquired immunodeficiency syndrome	9.68e-05	0.000412	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	9.65e-05	0.000411	CcSEcCtD
Carvedilol—Anorexia—Lamivudine—acquired immunodeficiency syndrome	9.63e-05	0.000411	CcSEcCtD
Carvedilol—Insomnia—Saquinavir—acquired immunodeficiency syndrome	9.58e-05	0.000408	CcSEcCtD
Carvedilol—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	9.57e-05	0.000408	CcSEcCtD
Carvedilol—Nausea—Abacavir—acquired immunodeficiency syndrome	9.53e-05	0.000406	CcSEcCtD
Carvedilol—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	9.51e-05	0.000405	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	9.5e-05	0.000405	CcSEcCtD
Carvedilol—Fatigue—Ritonavir—acquired immunodeficiency syndrome	9.49e-05	0.000404	CcSEcCtD
Carvedilol—Urticaria—Delavirdine—acquired immunodeficiency syndrome	9.46e-05	0.000403	CcSEcCtD
Carvedilol—Asthenia—Indinavir—acquired immunodeficiency syndrome	9.45e-05	0.000403	CcSEcCtD
Carvedilol—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	9.45e-05	0.000403	CcSEcCtD
Carvedilol—Hypotension—Lamivudine—acquired immunodeficiency syndrome	9.44e-05	0.000403	CcSEcCtD
Carvedilol—Somnolence—Saquinavir—acquired immunodeficiency syndrome	9.42e-05	0.000401	CcSEcCtD
Carvedilol—Constipation—Ritonavir—acquired immunodeficiency syndrome	9.41e-05	0.000401	CcSEcCtD
Carvedilol—Pain—Ritonavir—acquired immunodeficiency syndrome	9.41e-05	0.000401	CcSEcCtD
Carvedilol—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	9.41e-05	0.000401	CcSEcCtD
Carvedilol—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	9.41e-05	0.000401	CcSEcCtD
Carvedilol—Dizziness—Zidovudine—acquired immunodeficiency syndrome	9.36e-05	0.000399	CcSEcCtD
Carvedilol—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	9.33e-05	0.000397	CcSEcCtD
Carvedilol—Pruritus—Indinavir—acquired immunodeficiency syndrome	9.32e-05	0.000397	CcSEcCtD
Carvedilol—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	9.21e-05	0.000393	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	9.21e-05	0.000392	CcSEcCtD
Carvedilol—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	9.17e-05	0.000391	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	9.15e-05	0.00039	CcSEcCtD
Carvedilol—Insomnia—Lamivudine—acquired immunodeficiency syndrome	9.14e-05	0.00039	CcSEcCtD
Carvedilol—Fatigue—Saquinavir—acquired immunodeficiency syndrome	9.13e-05	0.000389	CcSEcCtD
Carvedilol—ABCB1—nervous system—acquired immunodeficiency syndrome	9.11e-05	0.000832	CbGeAlD
Carvedilol—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	9.08e-05	0.000387	CcSEcCtD
Carvedilol—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	9.07e-05	0.000387	CcSEcCtD
Carvedilol—Pain—Saquinavir—acquired immunodeficiency syndrome	9.06e-05	0.000386	CcSEcCtD
Carvedilol—Constipation—Saquinavir—acquired immunodeficiency syndrome	9.06e-05	0.000386	CcSEcCtD
Carvedilol—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	9.01e-05	0.000384	CcSEcCtD
Carvedilol—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	9.01e-05	0.000384	CcSEcCtD
Carvedilol—Vomiting—Zidovudine—acquired immunodeficiency syndrome	9e-05	0.000384	CcSEcCtD
Carvedilol—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	9e-05	0.000384	CcSEcCtD
Carvedilol—Somnolence—Lamivudine—acquired immunodeficiency syndrome	8.99e-05	0.000383	CcSEcCtD
Carvedilol—Rash—Zidovudine—acquired immunodeficiency syndrome	8.93e-05	0.00038	CcSEcCtD
Carvedilol—Asthenia—Efavirenz—acquired immunodeficiency syndrome	8.93e-05	0.00038	CcSEcCtD
Carvedilol—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	8.92e-05	0.00038	CcSEcCtD
Carvedilol—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	8.9e-05	0.000379	CcSEcCtD
Carvedilol—Headache—Zidovudine—acquired immunodeficiency syndrome	8.87e-05	0.000378	CcSEcCtD
Carvedilol—Pruritus—Efavirenz—acquired immunodeficiency syndrome	8.8e-05	0.000375	CcSEcCtD
Carvedilol—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	8.79e-05	0.000374	CcSEcCtD
Carvedilol—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	8.77e-05	0.000374	CcSEcCtD
Carvedilol—ABCB1—central nervous system—acquired immunodeficiency syndrome	8.77e-05	0.000801	CbGeAlD
Carvedilol—Urticaria—Ritonavir—acquired immunodeficiency syndrome	8.74e-05	0.000373	CcSEcCtD
Carvedilol—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	8.73e-05	0.000372	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	8.73e-05	0.000372	CcSEcCtD
Carvedilol—Fatigue—Lamivudine—acquired immunodeficiency syndrome	8.71e-05	0.000371	CcSEcCtD
Carvedilol—Dizziness—Indinavir—acquired immunodeficiency syndrome	8.71e-05	0.000371	CcSEcCtD
Carvedilol—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	8.7e-05	0.000371	CcSEcCtD
Carvedilol—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	8.7e-05	0.000371	CcSEcCtD
Carvedilol—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	8.66e-05	0.000369	CcSEcCtD
Carvedilol—Pain—Lamivudine—acquired immunodeficiency syndrome	8.64e-05	0.000368	CcSEcCtD
Carvedilol—Constipation—Lamivudine—acquired immunodeficiency syndrome	8.64e-05	0.000368	CcSEcCtD
Carvedilol—Asthenia—Delavirdine—acquired immunodeficiency syndrome	8.54e-05	0.000364	CcSEcCtD
Carvedilol—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	8.51e-05	0.000363	CcSEcCtD
Carvedilol—Pruritus—Delavirdine—acquired immunodeficiency syndrome	8.42e-05	0.000359	CcSEcCtD
Carvedilol—Urticaria—Saquinavir—acquired immunodeficiency syndrome	8.42e-05	0.000359	CcSEcCtD
Carvedilol—Nausea—Zidovudine—acquired immunodeficiency syndrome	8.41e-05	0.000358	CcSEcCtD
Carvedilol—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	8.38e-05	0.000357	CcSEcCtD
Carvedilol—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	8.38e-05	0.000357	CcSEcCtD
Carvedilol—Vomiting—Indinavir—acquired immunodeficiency syndrome	8.37e-05	0.000357	CcSEcCtD
Carvedilol—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	8.33e-05	0.000355	CcSEcCtD
Carvedilol—Rash—Indinavir—acquired immunodeficiency syndrome	8.3e-05	0.000354	CcSEcCtD
Carvedilol—Dermatitis—Indinavir—acquired immunodeficiency syndrome	8.29e-05	0.000354	CcSEcCtD
Carvedilol—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	8.26e-05	0.000352	CcSEcCtD
Carvedilol—Headache—Indinavir—acquired immunodeficiency syndrome	8.25e-05	0.000352	CcSEcCtD
Carvedilol—Dizziness—Efavirenz—acquired immunodeficiency syndrome	8.23e-05	0.000351	CcSEcCtD
Carvedilol—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	8.14e-05	0.000347	CcSEcCtD
Carvedilol—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	8.11e-05	0.000346	CcSEcCtD
Carvedilol—Urticaria—Lamivudine—acquired immunodeficiency syndrome	8.03e-05	0.000342	CcSEcCtD
Carvedilol—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	7.99e-05	0.000341	CcSEcCtD
Carvedilol—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	7.99e-05	0.000341	CcSEcCtD
Carvedilol—Vomiting—Efavirenz—acquired immunodeficiency syndrome	7.91e-05	0.000337	CcSEcCtD
Carvedilol—Asthenia—Ritonavir—acquired immunodeficiency syndrome	7.9e-05	0.000337	CcSEcCtD
Carvedilol—Dizziness—Delavirdine—acquired immunodeficiency syndrome	7.87e-05	0.000335	CcSEcCtD
Carvedilol—Rash—Efavirenz—acquired immunodeficiency syndrome	7.84e-05	0.000334	CcSEcCtD
Carvedilol—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	7.84e-05	0.000334	CcSEcCtD
Carvedilol—Nausea—Indinavir—acquired immunodeficiency syndrome	7.82e-05	0.000333	CcSEcCtD
Carvedilol—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	7.81e-05	0.000333	CcSEcCtD
Carvedilol—Headache—Efavirenz—acquired immunodeficiency syndrome	7.79e-05	0.000332	CcSEcCtD
Carvedilol—Pruritus—Ritonavir—acquired immunodeficiency syndrome	7.79e-05	0.000332	CcSEcCtD
Carvedilol—Asthenia—Saquinavir—acquired immunodeficiency syndrome	7.6e-05	0.000324	CcSEcCtD
Carvedilol—Vomiting—Delavirdine—acquired immunodeficiency syndrome	7.57e-05	0.000323	CcSEcCtD
Carvedilol—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	7.53e-05	0.000321	CcSEcCtD
Carvedilol—Rash—Delavirdine—acquired immunodeficiency syndrome	7.51e-05	0.00032	CcSEcCtD
Carvedilol—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	7.5e-05	0.00032	CcSEcCtD
Carvedilol—Pruritus—Saquinavir—acquired immunodeficiency syndrome	7.5e-05	0.000319	CcSEcCtD
Carvedilol—Headache—Delavirdine—acquired immunodeficiency syndrome	7.46e-05	0.000318	CcSEcCtD
Carvedilol—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	7.45e-05	0.000317	CcSEcCtD
Carvedilol—Nausea—Efavirenz—acquired immunodeficiency syndrome	7.39e-05	0.000315	CcSEcCtD
Carvedilol—Dizziness—Ritonavir—acquired immunodeficiency syndrome	7.28e-05	0.00031	CcSEcCtD
Carvedilol—Asthenia—Lamivudine—acquired immunodeficiency syndrome	7.25e-05	0.000309	CcSEcCtD
Carvedilol—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	7.25e-05	0.000309	CcSEcCtD
Carvedilol—Pruritus—Lamivudine—acquired immunodeficiency syndrome	7.15e-05	0.000305	CcSEcCtD
Carvedilol—Nausea—Delavirdine—acquired immunodeficiency syndrome	7.07e-05	0.000301	CcSEcCtD
Carvedilol—Dizziness—Saquinavir—acquired immunodeficiency syndrome	7.01e-05	0.000299	CcSEcCtD
Carvedilol—Vomiting—Ritonavir—acquired immunodeficiency syndrome	7e-05	0.000298	CcSEcCtD
Carvedilol—ABCB1—brain—acquired immunodeficiency syndrome	6.96e-05	0.000636	CbGeAlD
Carvedilol—Rash—Ritonavir—acquired immunodeficiency syndrome	6.94e-05	0.000296	CcSEcCtD
Carvedilol—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	6.93e-05	0.000296	CcSEcCtD
Carvedilol—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	6.92e-05	0.000295	CcSEcCtD
Carvedilol—Headache—Ritonavir—acquired immunodeficiency syndrome	6.9e-05	0.000294	CcSEcCtD
Carvedilol—Vomiting—Saquinavir—acquired immunodeficiency syndrome	6.74e-05	0.000287	CcSEcCtD
Carvedilol—ABCB1—lymph node—acquired immunodeficiency syndrome	6.73e-05	0.000615	CbGeAlD
Carvedilol—Dizziness—Lamivudine—acquired immunodeficiency syndrome	6.68e-05	0.000285	CcSEcCtD
Carvedilol—Rash—Saquinavir—acquired immunodeficiency syndrome	6.68e-05	0.000285	CcSEcCtD
Carvedilol—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	6.67e-05	0.000284	CcSEcCtD
Carvedilol—Headache—Saquinavir—acquired immunodeficiency syndrome	6.64e-05	0.000283	CcSEcCtD
Carvedilol—Nausea—Ritonavir—acquired immunodeficiency syndrome	6.54e-05	0.000279	CcSEcCtD
Carvedilol—Vomiting—Lamivudine—acquired immunodeficiency syndrome	6.43e-05	0.000274	CcSEcCtD
Carvedilol—Rash—Lamivudine—acquired immunodeficiency syndrome	6.37e-05	0.000272	CcSEcCtD
Carvedilol—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	6.37e-05	0.000271	CcSEcCtD
Carvedilol—Headache—Lamivudine—acquired immunodeficiency syndrome	6.33e-05	0.00027	CcSEcCtD
Carvedilol—Nausea—Saquinavir—acquired immunodeficiency syndrome	6.29e-05	0.000268	CcSEcCtD
Carvedilol—Nausea—Lamivudine—acquired immunodeficiency syndrome	6e-05	0.000256	CcSEcCtD
Carvedilol—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	2.59e-05	0.00037	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.58e-05	0.000368	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.58e-05	0.000368	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.57e-05	0.000366	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.57e-05	0.000366	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.56e-05	0.000366	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.54e-05	0.000362	CbGpPWpGaD
Carvedilol—ADRA2A—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	2.54e-05	0.000362	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.53e-05	0.000361	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.53e-05	0.000361	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.53e-05	0.000361	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.52e-05	0.00036	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.52e-05	0.00036	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.51e-05	0.000358	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.51e-05	0.000358	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.51e-05	0.000358	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.5e-05	0.000357	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.5e-05	0.000357	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.5e-05	0.000356	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.5e-05	0.000356	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.48e-05	0.000354	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—CSF2—acquired immunodeficiency syndrome	2.47e-05	0.000353	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.47e-05	0.000352	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.47e-05	0.000352	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—IL6—acquired immunodeficiency syndrome	2.46e-05	0.00035	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	2.44e-05	0.000349	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.44e-05	0.000348	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	2.42e-05	0.000346	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.4e-05	0.000342	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.39e-05	0.000341	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.37e-05	0.000338	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—IL6—acquired immunodeficiency syndrome	2.36e-05	0.000336	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.34e-05	0.000333	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.33e-05	0.000333	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.33e-05	0.000333	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.32e-05	0.000331	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.3e-05	0.000328	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.3e-05	0.000328	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.3e-05	0.000328	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.29e-05	0.000327	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.29e-05	0.000327	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.28e-05	0.000326	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.25e-05	0.00032	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.25e-05	0.00032	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.23e-05	0.000318	CbGpPWpGaD
Carvedilol—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.23e-05	0.000317	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.22e-05	0.000317	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.2e-05	0.000314	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.17e-05	0.00031	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.17e-05	0.000309	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.13e-05	0.000304	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.13e-05	0.000304	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—ALB—acquired immunodeficiency syndrome	2.13e-05	0.000303	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.11e-05	0.000301	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.11e-05	0.0003	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.09e-05	0.000298	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.09e-05	0.000298	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.09e-05	0.000298	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.09e-05	0.000298	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.08e-05	0.000297	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	2.08e-05	0.000296	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.07e-05	0.000296	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.07e-05	0.000296	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	2.07e-05	0.000295	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.07e-05	0.000295	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.06e-05	0.000294	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	2.06e-05	0.000294	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.04e-05	0.000291	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.04e-05	0.000291	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.04e-05	0.00029	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.02e-05	0.000288	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—ALB—acquired immunodeficiency syndrome	1.99e-05	0.000283	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.95e-05	0.000279	CbGpPWpGaD
Carvedilol—HIF1A—Disease—IL6—acquired immunodeficiency syndrome	1.93e-05	0.000275	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.93e-05	0.000275	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.93e-05	0.000275	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.92e-05	0.000274	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.92e-05	0.000274	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.92e-05	0.000274	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.91e-05	0.000272	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.9e-05	0.000272	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.9e-05	0.000271	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.9e-05	0.000271	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.9e-05	0.00027	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.9e-05	0.00027	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.9e-05	0.00027	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.9e-05	0.00027	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.89e-05	0.000269	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.89e-05	0.000269	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.88e-05	0.000268	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.88e-05	0.000268	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.88e-05	0.000268	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.87e-05	0.000267	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.86e-05	0.000265	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.85e-05	0.000264	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.85e-05	0.000264	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.85e-05	0.000263	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.8e-05	0.000257	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.78e-05	0.000253	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.76e-05	0.000251	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.76e-05	0.000251	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.75e-05	0.00025	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.75e-05	0.00025	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.75e-05	0.000249	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.75e-05	0.000249	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.74e-05	0.000248	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.74e-05	0.000248	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.73e-05	0.000247	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.73e-05	0.000246	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—IL2—acquired immunodeficiency syndrome	1.72e-05	0.000246	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.72e-05	0.000245	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.72e-05	0.000245	CbGpPWpGaD
Carvedilol—XDH—Metabolism—ALB—acquired immunodeficiency syndrome	1.72e-05	0.000245	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.72e-05	0.000245	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.71e-05	0.000244	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.71e-05	0.000244	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.71e-05	0.000244	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.69e-05	0.000241	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.68e-05	0.00024	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.68e-05	0.00024	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.64e-05	0.000234	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.63e-05	0.000233	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.63e-05	0.000233	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.62e-05	0.000231	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	1.61e-05	0.00023	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—IL2—acquired immunodeficiency syndrome	1.61e-05	0.00023	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.6e-05	0.000228	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.6e-05	0.000228	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.6e-05	0.000228	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.59e-05	0.000226	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.58e-05	0.000226	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.57e-05	0.000224	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.57e-05	0.000224	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.56e-05	0.000223	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.55e-05	0.000221	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.55e-05	0.000221	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.54e-05	0.00022	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.53e-05	0.000218	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.49e-05	0.000212	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.49e-05	0.000212	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.48e-05	0.00021	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.48e-05	0.00021	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.47e-05	0.000209	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.46e-05	0.000208	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.46e-05	0.000208	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.44e-05	0.000206	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.44e-05	0.000206	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.44e-05	0.000205	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.43e-05	0.000204	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.42e-05	0.000203	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.42e-05	0.000202	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.4e-05	0.000199	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.38e-05	0.000197	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.38e-05	0.000197	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.36e-05	0.000194	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.36e-05	0.000193	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.36e-05	0.000193	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.35e-05	0.000193	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.32e-05	0.000188	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	1.31e-05	0.000187	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.3e-05	0.000185	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.28e-05	0.000183	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.27e-05	0.000181	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.24e-05	0.000177	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.22e-05	0.000175	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.21e-05	0.000172	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.21e-05	0.000172	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.21e-05	0.000172	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.19e-05	0.00017	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.13e-05	0.000162	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.12e-05	0.00016	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.12e-05	0.00016	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.12e-05	0.00016	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.12e-05	0.00016	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.12e-05	0.000159	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.11e-05	0.000158	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.11e-05	0.000158	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000157	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000156	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.09e-05	0.000156	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.09e-05	0.000155	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.08e-05	0.000153	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.05e-05	0.00015	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.03e-05	0.000147	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.03e-05	0.000147	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.02e-05	0.000146	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.02e-05	0.000145	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.02e-05	0.000145	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.01e-05	0.000144	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1e-05	0.000143	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.99e-06	0.000142	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.98e-06	0.000142	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.94e-06	0.000142	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.92e-06	0.000141	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.89e-06	0.000141	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.89e-06	0.000141	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.77e-06	0.000139	CbGpPWpGaD
Carvedilol—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	9.65e-06	0.000138	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	9.49e-06	0.000135	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.45e-06	0.000135	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.3e-06	0.000133	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.24e-06	0.000132	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.17e-06	0.000131	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.09e-06	0.00013	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.03e-06	0.000129	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.9e-06	0.000127	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.52e-06	0.000121	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.39e-06	0.00012	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.27e-06	0.000118	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.26e-06	0.000118	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	8.11e-06	0.000116	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.08e-06	0.000115	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	8.05e-06	0.000115	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—ALB—acquired immunodeficiency syndrome	8.04e-06	0.000115	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.67e-06	0.000109	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.51e-06	0.000107	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	6.54e-06	9.33e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.47e-06	9.23e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.44e-06	9.19e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ALB—acquired immunodeficiency syndrome	6.01e-06	8.56e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.9e-06	8.41e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.87e-06	8.37e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.84e-06	8.34e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.84e-06	8.33e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.83e-06	8.31e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.81e-06	8.29e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.77e-06	8.23e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.74e-06	8.19e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ALB—acquired immunodeficiency syndrome	5.66e-06	8.07e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.46e-06	7.79e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.43e-06	7.75e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.37e-06	7.66e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.35e-06	7.62e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.77e-06	6.81e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.75e-06	6.77e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	4.52e-06	6.45e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.43e-06	6.32e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.41e-06	6.29e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	4.26e-06	6.08e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	4.22e-06	6.03e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.8e-06	5.43e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	3.61e-06	5.15e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.47e-06	4.94e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.44e-06	4.9e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.39e-06	4.84e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.21e-06	4.58e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.16e-06	4.5e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.8e-06	4e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.79e-06	3.97e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.61e-06	3.72e-05	CbGpPWpGaD
